Archer Materials (ASX:AXE) said its biochip program remains on track to deliver a laboratory demonstrator for sensing blood potassium in patients with chronic kidney disease, a key step before external trials, according to a Friday filing with the Australian bourse.
Shares of the company fell past 3% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.